U.S. Markets open in 7 hrs 16 mins

TrovaGene, Inc. (TROV)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.81-0.03 (-3.57%)
At close: 4:00PM EDT
People also watch

TrovaGene, Inc.

11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States

IndustryMedical Laboratories & Research
Full Time Employees55

Key Executives

Mr. William J. Welch M.B.A.Chief Exec. Officer, Principal Financial Officer and Director435.49kN/A55
Dr. Mark Erlander Ph.D.Chief Scientific Officer608.4kN/A57
Dr. Karsten Schmidt Ph.D.Chief Technology OfficerN/AN/A55
Ms. Elizabeth Anderson CPAVP of Fin. and Admin.N/AN/AN/A
Mr. George Samuel J.D.VP & Gen. CounselN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Corporate Governance

TrovaGene, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.